These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 11958494)

  • 1. Testing for factor V Leiden in patients with pulmonary or venous thromboembolism: a cost-effectiveness analysis.
    Eckman MH; Singh SK; Erban JK; Kao G
    Med Decis Making; 2002; 22(2):108-24. PubMed ID: 11958494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden--cost-effectiveness analysis.
    Marchetti M; Pistorio A; Barosi G
    Thromb Haemost; 2000 Nov; 84(5):752-7. PubMed ID: 11127850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulation duration in heterozygous factor V Leiden: a decision analysis.
    Donovan AK; Smith KJ; Ragni MV
    Thromb Res; 2013; 132(6):724-8. PubMed ID: 24112753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation.
    Tzoran I; Papadakis M; Brenner B; Fidalgo Á; Rivas A; Wells PS; Gavín O; Adarraga MD; Moustafa F; Monreal M;
    Am J Med; 2017 Apr; 130(4):482.e1-482.e9. PubMed ID: 27986523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.
    Eichinger S; Pabinger I; Stümpflen A; Hirschl M; Bialonczyk C; Schneider B; Mannhalter C; Minar E; Lechner K; Kyrle PA
    Thromb Haemost; 1997 Apr; 77(4):624-8. PubMed ID: 9134632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.
    Emmerich J; Rosendaal FR; Cattaneo M; Margaglione M; De Stefano V; Cumming T; Arruda V; Hillarp A; Reny JL
    Thromb Haemost; 2001 Sep; 86(3):809-16. PubMed ID: 11583312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A.
    Marchetti M; Quaglini S; Barosi G
    QJM; 2001 Jul; 94(7):365-72. PubMed ID: 11435632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation: rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial.
    Ridker PM
    Vasc Med; 1998; 3(1):67-73. PubMed ID: 9666536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism.
    Eichinger S; Weltermann A; Mannhalter C; Minar E; Bialonczyk C; Hirschl M; Schönauer V; Lechner K; Kyrle PA
    Arch Intern Med; 2002 Nov; 162(20):2357-60. PubMed ID: 12418950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do incident and recurrent venous thromboembolism risks truly differ between heterozygous and homozygous Factor V Leiden carriers? A retrospective cohort study.
    Perez Botero J; Ormsby WD; Ashrani AA; McBane RD; Wysokinski WE; Patnaik MM; Lewis BR; Grill DE; Pruthi RK; Heit JA
    Eur J Intern Med; 2016 May; 30():77-81. PubMed ID: 26970916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism.
    Ridker PM; Miletich JP; Stampfer MJ; Goldhaber SZ; Lindpaintner K; Hennekens CH
    Circulation; 1995 Nov; 92(10):2800-2. PubMed ID: 7586244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasminogen activator inhibitor-1 4G/5G polymorphism, factor V Leiden, prothrombin mutations and the risk of VTE recurrence.
    Sundquist K; Wang X; Svensson PJ; Sundquist J; Hedelius A; Larsson Lönn S; Zöller B; Memon AA
    Thromb Haemost; 2015 Nov; 114(6):1156-64. PubMed ID: 26245493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation.
    De Stefano V; Martinelli I; Mannucci PM; Paciaroni K; Chiusolo P; Casorelli I; Rossi E; Leone G
    N Engl J Med; 1999 Sep; 341(11):801-6. PubMed ID: 10477778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral anticoagulation strategies after a first idiopathic venous thromboembolic event.
    Aujesky D; Smith KJ; Roberts MS
    Am J Med; 2005 Jun; 118(6):625-35. PubMed ID: 15922694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of guidelines for insertion of inferior vena cava filters in high-risk trauma patients.
    Spangler EL; Dillavou ED; Smith KJ
    J Vasc Surg; 2010 Dec; 52(6):1537-45.e1-2. PubMed ID: 20843631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery.
    Wåhlander K; Larson G; Lindahl TL; Andersson C; Frison L; Gustafsson D; Bylock A; Eriksson BI
    Thromb Haemost; 2002 Apr; 87(4):580-5. PubMed ID: 12008938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective.
    Seaman CD; Smith KJ; Ragni MV
    Thromb Res; 2013; 132(6):647-51. PubMed ID: 24139508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High frequency of factor V Leiden in surgical patients with symptomatic venous thromboembolism despite prophylaxis.
    Baba-Ahmed M; Le Gal G; Couturaud F; Lacut K; Oger E; Leroyer C
    Thromb Haemost; 2007 Feb; 97(2):171-5. PubMed ID: 17264942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is recurrent venous thromboembolism more frequent in homozygous patients for the factor V Leiden mutation than in heterozygous patients?
    Procare Group
    Blood Coagul Fibrinolysis; 2003 Sep; 14(6):523-9. PubMed ID: 12960604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.
    Ruggeri M; Gisslinger H; Tosetto A; Rintelen C; Mannhalter C; Pabinger I; Heis N; Castaman G; Missiaglia E; Lechner K; Rodeghiero F
    Am J Hematol; 2002 Sep; 71(1):1-6. PubMed ID: 12221665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.